Table 2.
Associations between Complete Remission, Overall Survival and DNA Repair Gene Polymorphisms
| Complete Remission (CR) * | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | CR, Overall | CR in de novo AML | CR in Secondary AML | ||||||||
| Polymorphism | N | OR | CI | N | OR | CI | N | OR | CI | ||
| XRCC1 | |||||||||||
| Arg399Gln: | GG** | 137 | 73 | 1.00 | – | 106/64 | 1.00 | – | 31/9 | 1.00 | – |
| GA | 123 | 66 | 1.05 | 0.60–1.83 | 84/53 | 1.01 | 0.53–1.95 | 39/13 | 1.10 | 0.35–3.46 | |
| AA | 29 | 15 | 1.03 | 0.42– 2.50 | 20/10 | 0.65 | 0.23–1.86 | 9/5 | 2.56 | 0.44–14.79 | |
| GA or AA | 152 | 81 | 1.05 | 0.62–1.77 | 104/63 | 0.92 | 0.50–1.70 | 48/18 | 1.29 | 0.43–3.86 | |
| Total | 289 | 154 | |||||||||
| XPD | |||||||||||
| Lys751Gln: | AA** | 125 | 57 | 1.00 | – | 93/52 | 1.00 | – | 32/5 | 1.00 | – |
| AC | 118 | 68 | 2.00 | 1.12–3.56 | 90/55 | 1.39 | 0.72–2.67 | 28/13 | 9.52 | 2.10–43.12 | |
| CC | 45 | 27 | 2.22 | 1.00– 4.91 | 27/19 | 1.68 | 0.61–4.60 | 18/8 | 7.07 | 1.42–35.18 | |
| AC or CC | 163 | 95 | 2.05 | 1.20–3.52 | 117/74 | 1.44 | 0.78–2.68 | 46/21 | 8.42 | 2.08–34.01 | |
| Total | 288 | 152 | |||||||||
| XPD | |||||||||||
| Asp312Asn: | GG** | 127 | 60 | 1.00 | – | 93/53 | 1.00 | – | 34/7 | 1.00 | – |
| GA | 113 | 64 | 1.54 | 0.86–2.75 | 90/54 | 1.24 | 0.64–2.40 | 23/10 | 3.39 | 0.89–12.85 | |
| AA | 37 | 26 | 4.34 | 1.80–10.48 | 21/16 | 2.97 | 0.95–9.23 | 16/10 | 11.23 | 2.23–56.63 | |
| GA or AA | 150 | 90 | 1.98 | 1.15–3.40 | 111/70 | 1.47 | 0.79–2.75 | 39/20 | 5.19 | 1.54–17.51 | |
| Total | 277 | 150 | |||||||||
| Overall Survival (OS) | |||||||||||
| Total | OS | OS in de novo AML | OS in Secondary AML | ||||||||
| Polymorphism | N | Deaths | HR | CI | Deaths | HR | CI | Deaths | HR | CI | |
| XRCC1 | |||||||||||
| Arg399Gln: | GG | 137 | 107 | 1.00 | – | 78 | 1.00 | – | 29 | 1.00 | – |
| GA | 123 | 97 | 0.96 | 0.72–1.27 | 62 | 1.05 | 0.75–1.48 | 35 | 0.84 | 0.48–1.46 | |
| AA | 29 | 20 | 0.77 | 0.48–1.25 | 12 | 0.89 | 0.48–1.64 | 8 | 0.56 | 0.23–1.35 | |
| GA or AA | 152 | 117 | 0.92 | 0.70–1.20 | 74 | 1.02 | 0.74–1.40 | 43 | 0.78 | 0.46–1.33 | |
| Total | 289 | 224 | 152 | 72 | |||||||
| XPD | |||||||||||
| Lys751Gln: | AA | 125 | 99 | 1.00 | – | 69 | 1.00 | – | 30 | 1.00 | – |
| AC | 118 | 91 | 0.86 | 0.65–1.15 | 65 | 1.00 | 0.71–1.41 | 26 | 0.59 | 0.34–1.04 | |
| CC | 45 | 35 | 0.81 | 0.54–1.21 | 20 | 1.15 | 0.69–1.92 | 15 | 0.46 | 0.24–0.88 | |
| AC or CC | 163 | 126 | 0.85 | 0.65–1.11 | 85 | 1.03 | 0.75–1.42 | 41 | 0.53 | 0.32–0.88 | |
| Total | 288 | 225 | 154 | 71 | |||||||
| XPD | |||||||||||
| Asp312Asn: | GG | 127 | 94 | 1.00 | – | 62 | 1.00 | – | 32 | 1.00 | – |
| GA | 113 | 91 | 1.01 | 0.76–1.36 | 71 | 1.32 | 0.93–1.86 | 20 | 0.48 | 0.26–0.86 | |
| AA | 37 | 29 | 0.77 | 0.50–1.19 | 15 | 1.09 | 0.61–1.93 | 14 | 0.39 | 0.20–0.79 | |
| GA or AA | 150 | 120 | 0.95 | 0.72–1.25 | 86 | 1.27 | 0.91–1.77 | 34 | 0.44 | 0.26–0.75 | |
| Total | 277 | 214 | 148 | 66 | |||||||
*
CR and OS estimates are adjusted for the following covariates: age, cytogenetic group, white blood cell count, HSCT
**
Referent genotype